临床肝胆病杂志2011，Vol.27Issue(1)：89-92,4.
丙型肝炎肝硬化的"分级"及聚乙二醇干扰素α-2a联合利巴韦林的抗病毒治疗
Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy
摘要
Abstract
Objective To investigate the clinical efficacy of antiviral therapy in patients with HCV related cirrhosis and to establish the grading of standard antivirai therapy for these patients. Methods 82 patients diagnosed with HCV related cirrhosis were included in this study, and were divided into 3 groups depending on the degree of cirrhosis, hypersplenism and the tolerance of treatment. After treating with hematopoietic growth factors, partial splenic embolization or splenectomy, the improvement of hypersplenism was observed. Based on the standard antiviral therapy, more active response guided therapy were used to achieve more ideal effect. The effect of treatment and the liver function were analyzed. 32 patients with chronic hepatitis C were studied as control. Results The count of white blood cells and platelets were increased significantly. The EVR rate of partial splenic embolization and splenectomy were about 60％, and the SVR rate were 59.3％ and 63.6％ respectively. The levels of ALT were decreased significantly. Conclusion We propose the grading strategy of antiviral therapy for patients with HCV related cirrhosis, which could slow down the rate of progression of the cirrhosis and improve the quality of life.关键词
肝硬化/肝炎病毒属/干扰素α-2a/利巴韦林/抗病毒药Key words
liver cirrhosis/ hepacivirus/ interferon alfa-2a/ Ribavirin/ antiviral agents分类
医药卫生引用本文复制引用
魏欣,谢玉梅,陈琳,潘蕾,郝春秋,王九平,白雪帆,贾战生..丙型肝炎肝硬化的"分级"及聚乙二醇干扰素α-2a联合利巴韦林的抗病毒治疗[J].临床肝胆病杂志,2011,27(1):89-92,4.基金项目
国家"863"专项课题(2007AA02Z441) （2007AA02Z441）
"十一五"重大传染病防治专项课题(2009ZX10004-715) （2009ZX10004-715）
